Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...
The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent ...
A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
SMART control of CAR T cells is advancing cancer immunotherapy by improving precision, safety, and adaptability. Why Smart ...
BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...
Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...
UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...
CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...
The breakthrough, published Tuesday in the journal Cell, offers a promising new strategy to combat relapse, which occurs in ...
Eurofins Viracor, a leader in advanced clinical diagnostics, today announced the launch of the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results